COCP is the ticker symbol for Cocrystal Pharma, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks COCP with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is COCP a good stock to buy?

COCP is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/COCP.

Where does 13F Pro source COCP data?

All Cocrystal Pharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cocrystal Pharma, Inc. files with the SEC under CIK 1412486. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Cocrystal Pharma, Inc.(COCP)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Cocrystal Pharma, Inc. (COCP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. COCP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 28 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q2 2026), Cocrystal Pharma, Inc. reports quarterly revenue of $105.0K, net income of $-3.2M. Top institutional holders of COCP by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. COCP trades on the Nasdaq exchange and files with the SEC under CIK 1412486. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COCP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cocrystal Pharma, Inc. directly from SEC EDGAR.

Revenue

$105.0K

Net Income

$-3.2M

COCP key financials by period

Cocrystal Pharma, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2020	10-K	$2.0M	$-9.6M	—
FY 2019	10-K	$6.6M	$-48.2M	—
FY 2014	10-K	$733.0K	$-99.0K	—
FY 2011	10-K	$12.7M	$-5.5M	-30.6%

Institutions holding COCP

Institutional investors reporting a position in Cocrystal Pharma, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
VANGUARD CAPITAL MANAGEMENT	358,228	$376.1K	2026-06-30
RENAISSANCE TECHNOLOGIES	179,628	$188.6K	2026-06-30
TWO SIGMA INVESTMENTS	175,379	$184.1K	2026-06-30
GEODE CAPITAL MANAGEMENT	76,208	$80.0K	2026-06-30
BlackRock	73,746	$77.4K	2026-06-30
CITADEL ADVISORS	45,118	$47.4K	2026-06-30
Neuberger Berman Group	31,886	$33.5K	2026-06-30
XTX Topco Ltd	29,342	$30.8K	2026-06-30
JANE STREET GROUP	25,761	$27.0K	2026-06-30
VANGUARD FIDUCIARY	24,016	$25.2K	2026-06-30

SEC EDGAR: CIK 1412486 →

Cocrystal Pharma, Inc.

COCP

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 28 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.